• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Weekly semaglutide associated with reduced BMI in adolescents with obesity

byDavid XiangandKiera Liblik
December 26, 2022
in Chronic Disease, Pediatrics
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. In adolescents with obesity, semaglutide plus lifestyle intervention resulted in a significant body mass index (BMI) reduction compared to lifestyle intervention alone.

2. The semaglutide group had a greater reduction in waist circumference and levels of glycated hemoglobin compared to lifestyle intervention alone. 

Evidence Rating Level: 1 (Excellent)

Study Rundown: For adolescents with obesity, multimodal lifestyle modification is typically recommended. Though, associated reductions in BMI are generally modest. Pharmacotherapy can be considered, but options are limited. Semaglutide is a glucagon-like peptide 1 (GLP1) agonist that induces weight loss by decreasing appetite, thereby improving control of eating and reducing energy intake. Semaglutide is approved for long-term weight management as an adjunct to a reduced-calorie diet and increased physical activity for adults with obesity or for adults with overweight who have weight-related coexisting conditions. However, there is a gap in knowledge as to understanding whether once-weekly semaglutide plus lifestyle intervention is effective among adolescents with obesity. Overall, this study found that in adolescents with obesity, once-weekly semaglutide in addition to a lifestyle intervention resulted in a substantial reduction in BMI as compared with lifestyle intervention alone. This study has limited generalizability, as there were relatively small proportions of some racial and ethnic groups, and eight participants with type 2 diabetes, which may not be representative of the adolescent population in the United States. Nevertheless, the study’s findings demonstrate that once-weekly semaglutide provides a significant reduction in BMI compared with lifestyle modification alone.

Click to read the study in NEJM

Relevant Reading: Weight and Health — Pathophysiology and Therapies

RELATED REPORTS

Mazdutide significantly reduces weight in adults with overweight or obesity

Body mass index-specific waist circumference thresholds may improve mortality risk stratification in women

Abridge drafts pediatric notes so physicians stay with the kids, not the keyboard

In-Depth [randomized controlled trial]: This double-blind, randomized, placebo-controlled clinical trial was conducted from October 2019 through March 2022. Patients who were adolescents (12 to 17 years of age) with a BMI in the 95th percentile or higher (according to sex and age-specific growth charts) and those with a BMI in the 85th percentile or higher who had at least one weight-related coexisting condition with at least one unsuccessful dietary weight loss effort were eligible for the study. Patients who had a weight change of more than 5kg, previous bariatric surgery, uncontrolled thyroid disease, secondary cause of obesity, major depressive disorder within two years, diagnosis of severe psychiatric disorders, and history of suicide attempt were excluded from the study. The primary outcome measured was the percentage change in BMI. Outcomes in the primary analysis were assessed via efficacy analysis and two-sided 95% Confidence Intervals [CI]. Based on the primary analysis, the mean change in BMI from baseline to week 68 was −16.1% with semaglutide and 0.6% with placebo (estimated difference, −16.7%; 95% CI, −20.3 to −13.2). At week 68, 73% of the semaglutide group reported weight loss of 5% or more, as compared to 18% of the placebo group (estimated odds ratio, 14.0; 95% CI, 6.3 to 31.0). Reductions in body weight and improvement with respect to cardiometabolic risk factors (waist circumference and levels of glycated hemoglobin, lipids, and alanine aminotransferase) were greater with semaglutide than with placebo. Overall, this study demonstrates that once-weekly treatment of a 2.4mg dose of semaglutide plus lifestyle intervention resulted in a greater BMI reduction than lifestyle intervention alone in adolescents with obesity.

Image: PD

©2022 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: adolescent medicineAdolescent obesitybody mass index (BMI)childhood obesitychronic diseaseGLP-1 agonistobesitypediatricssemaglutidewaist circumference
Previous Post

Dapagliflozin reduces the risk of hospitalization in patients with chronic kidney disease

Next Post

Diabetes is a risk factor for high platelet reactivity post percutaneous coronary intervention

RelatedReports

Increasing maternal BMI linked to higher risk of cerebral palsy
Cardiology

Mazdutide significantly reduces weight in adults with overweight or obesity

July 11, 2025
Majority of obese tenth-graders already obese by fifth grade
Chronic Disease

Body mass index-specific waist circumference thresholds may improve mortality risk stratification in women

July 7, 2025
Baby-led weaning not linked to increased choking
AI Roundup

Abridge drafts pediatric notes so physicians stay with the kids, not the keyboard

July 7, 2025
Chronic Disease

Type 2 diabetes and abnormal amyloid concentrations are associated with accelerated brain atrophy

July 7, 2025
Next Post

Diabetes is a risk factor for high platelet reactivity post percutaneous coronary intervention

2 Minute Rewind November 29, 2021

Vitamin C supplementation in pregnant smokers leads to improved airway function in offspring

The Scan by 2 Minute Medicine®:  Ultra-Trail du Mont-Blanc, Taylor Swift, NBA rookie Chet Holmgren and Magic Mushrooms!

The Scan by 2 Minute Medicine®: the Future of Medicine, Neuralink, the Spotlight on Celine Dion and COVID-19 on Social Media

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • SGLT2 inhibitors may delay cognitive impairment in elderly patients with heart failure
  • Nerandomilast slows decline in FVC in idiopathic pulmonary fibrosis
  • Mazdutide significantly reduces weight in adults with overweight or obesity
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.